Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication

Abstract

The current antiretroviral therapy (ART) for human immunodeficiency virus (HIV) can halt viral replication but cannot eradicate HIV infection because proviral DNA integrated into the host genome remains genetically silent in reservoir cells and is replication-competent upon interruption or cessation of ART. CRISPR/Cas9-based technology is widely used to edit target genes via mutagenesis (i.e., nucleotide insertion/deletion and/or substitution) and thus can inactivate integrated proviral DNA. However, CRISPR/Cas9 delivery systems often require viral vectors, which pose safety concerns for therapeutic applications in humans. In this study, we used synthetic guide RNA (gRNA)/Cas9-ribonucleoprotein (RNP) as a non-viral formulation to develop a novel HIV gene therapy. We designed a series of gRNAs targeting different HIV genes crucial for HIV replication and tested their antiviral efficacy and cellular cytotoxicity in lymphoid and monocytic latent HIV cell lines. Compared with the scramble gRNA control, HIV-gRNA/Cas9 RNP-treated cells exhibited efficient viral suppression with no apparent cytotoxicity, as evidenced by the significant inhibition of latent HIV DNA reactivation and RNA replication. Moreover, HIV-gRNA/Cas9 RNP inhibited p24 antigen expression, suppressed infectious viral particle production, and generated specific DNA cleavages in the targeted HIV genes that are confirmed by DNA sequencing. Because of its rapid DNA cleavage, low off-target effects, low risk of insertional mutagenesis, easy production, and readiness for use in clinical application, this study provides a proof-of-concept that synthetic gRNA/Cas9 RNP drugs can be utilized as a novel therapeutic approach for HIV eradication.

Document Details

Document Type
Pub Defense Publication
Publication Date
Aug 28, 2022
Source ID
10.3390/v14091902

Entities

People

  • Dechao Cao
  • Jinyu Zhang
  • Jonathan P. Moorman
  • Juan Zhao
  • Lam Ngoc Thao Nguyen
  • Ling Wang
  • Madison Schank
  • Mohamed El Gazzar
  • Shunbin Ning
  • Sushant Khanal
  • Xiao Y. Wu
  • Xindi Dang
  • Yi Zhang
  • Yong Jiang
  • Zhi Q Yao

Organizations

  • National Institutes of Health
  • United States Department of Defense
  • United States Department of Veterans Affairs

Tags

Fields of Study

  • Biology

Readers

  • Immunology
  • Molecular Genetics
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech